Home >> Research Area >>Tyrosine Kinase/Adaptors>>PDGFR>> Pazopanib (GW-786034)

Pazopanib (GW-786034)

VEGFR/PDGFR/FGFR inhibitor CAS# 444731-52-6

Pazopanib (GW-786034)

Catalog No. BCC1286----Order now to get a substantial discount!

Product Name & Size Price Stock
Pazopanib (GW-786034): 5mg $17 In Stock
Pazopanib (GW-786034): 10mg Please Inquire In Stock
Pazopanib (GW-786034): 20mg Please Inquire Please Inquire
Pazopanib (GW-786034): 50mg Please Inquire Please Inquire
Pazopanib (GW-786034): 100mg Please Inquire Please Inquire
Pazopanib (GW-786034): 200mg Please Inquire Please Inquire
Pazopanib (GW-786034): 500mg Please Inquire Please Inquire
Pazopanib (GW-786034): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Pazopanib (GW-786034)

Number of papers citing our products

Chemical structure

Pazopanib (GW-786034)

3D structure

Chemical Properties of Pazopanib (GW-786034)

Cas No. 444731-52-6 SDF Download SDF
PubChem ID 10113978 Appearance Powder
Formula C21H23N7O2S M.Wt 437.52
Type of Compound N/A Storage Desiccate at -20°C
Synonyms GW786034
Solubility DMSO : ≥ 43 mg/mL (98.28 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Standard InChIKey CUIHSIWYWATEQL-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Pazopanib (GW-786034)

DescriptionPazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.
TargetsVEGFR1VEGFR2VEGFR3PDGFRFGFR  
IC5010 nM30 nM47 nM84 nM74 nM  

Protocol

Cell experiment: [1]

Cell lines

Primary human brain microvascular endothelial cells (HBMEC)

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

IC50: 2 μM, 48 hours

Applications

The IC50 for pazopanib for anchorage-dependent growth was 2 μM and 1 μM after 48 h and 72 h, respectively. Pazopanib abrogated the phosphorylation of VEGFR2 with disruption of downstream PLCγ1. It also disrupted the Ras-Raf-ERK pathway through decreased phosphorylated MEK1/2 and ERK1/2 and affected the phosphorylation of 70S6K. Our findings confirmed that pazopanib targeted endothelial cells, affecting cell growth, VEGFR-induced signaling, and tube formation.

Animal experiment: [2]

Animal models

Immune-deficient beige-nude-xid (BNX) mice injected with MM.1S cells

Dosage form

Oral administration, 30 mg/kg and 100 mg/kg, daily for five weeks

Application

Tumor growth in treated mice was significantly delayed (30 mg/kg) or almost totally inhibited (100 mg/kg) compared with the control group. However, tumors rapidly regrew after cessation of treatment at day 30. Using Kaplan–Meier and log-rank analysis, the mean overall survival (OS) was 20 days in the control cohort versus 41 days and 51 days in groups treated with 30 mg/kg and 100 mg/kg pazopanib, respectively. Statistically significant prolongation in mean OS compared with control mice was observed in animals treated with 30 mg/kg and 100 mg/kg. Importantly, treatment with either the vehicle alone or pazopanib did not affect body weight.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Gril B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clinical Cancer Research, 2011, 17(1): 142-153.

[2] Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences, 2006, 103(51): 19478-19483.

Pazopanib (GW-786034) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Pazopanib (GW-786034) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Pazopanib (GW-786034)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2856 mL 11.428 mL 22.8561 mL 45.7122 mL 57.1402 mL
5 mM 0.4571 mL 2.2856 mL 4.5712 mL 9.1424 mL 11.428 mL
10 mM 0.2286 mL 1.1428 mL 2.2856 mL 4.5712 mL 5.714 mL
50 mM 0.0457 mL 0.2286 mL 0.4571 mL 0.9142 mL 1.1428 mL
100 mM 0.0229 mL 0.1143 mL 0.2286 mL 0.4571 mL 0.5714 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Research Update of Pazopanib (GW-786034)

3. Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer. Anticancer Res. 2013 Sep;33(9):3823-9.
Abstract
Pazopanib is a substrate for ATP-binding cassette family transporter that exhibits anti-gynecological cancer activity in combination with metronomic topotecan.
4. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
Abstract
Due to a progression-free survival observed in previous studies, pazopanib and sunitinib have been assessed for efficacy and safety in a randomized trial.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Pazopanib (GW-786034)

Pazopanib is a potent and selective second generation multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit tyrosine kinases. It is involved in inhibiting signaling pathways, angiogenesis, and cell proliferation. Pazopanib exhibited excellent anti-angiogenic and anti-tumor activity and synergism was observed in combination with chemotherapeutic drugs in several mouse models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. It inhibits the intracellular tyrosine kinase portion of all the VEGFR subtypes, and exhibits distinct pharmacokinetic and toxicity profiles compared with other agents among VEGF signaling pathway inhibitors. Recent studies elucidated its importance of signaling cascades related to angiogenesis in the management of RCC.

Reference

Sonpavde G, Hutson T E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Current oncology reports. 2007; 9(2): 115 - 119.

Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences. 2006; 103(51): 19478 - 19483.

Featured Products
New Products
 

References on Pazopanib (GW-786034)

Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).[Pubmed:22749591]

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jul 15;901:85-92.

A simple, rapid and sensitive liquid chromatography-tandem mass spectrometric (LC/MS-MS) method has been developed and validated for the quantitative determination of pazopanib in mouse plasma and brain tissue homogenate. Single liquid-liquid extraction step with ethyl acetate was employed for analysis of pazopanib and the internal standard (IS); vandetanib. HPLC separation was performed on an XTerra((R)) MS C18 column 50 mm x 4.6 mm, 5.0 mum. The mobile phase consisted of 70% acetonitrile and 30% water with 0.1% formic acid, pumped at a flow rate of 0.25 ml/min. Analysis time was 3.5 min per run and both the analyte and IS eluted within 1.8-2.0 min. Multiple reactions monitoring (MRM) mode was utilized to detect the compounds of interest. The mass spectrometer was operated in the positive ion mode for detection. The precursor to product ions (Q1-->Q3) selected for pazopanib and internal standard during quantitative optimization were (m/z) 438.1-->357.2 and 475.0-->112.2 respectively. The calibration curves were linear over the range of 3.9-1000 ng/ml in both biological matrices. Lower limit of quantification (LLOQ) for mouse plasma and brain tissue was 3.9 ng/ml. The values for inter and intra day precision and accuracy were well within the ranges acceptable for analytical assessment (<15%). This method was applied to determine brain to plasma concentration ratio and relevant pharmacokinetic parameters of pazopanib after a single intravenous dose of 5 mg/kg in FVB wild type mice.

Description

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Keywords:

Pazopanib (GW-786034),444731-52-6,GW786034,Natural Products,PDGFR, buy Pazopanib (GW-786034) , Pazopanib (GW-786034) supplier , purchase Pazopanib (GW-786034) , Pazopanib (GW-786034) cost , Pazopanib (GW-786034) manufacturer , order Pazopanib (GW-786034) , high purity Pazopanib (GW-786034)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: